Dimasi Nazzareno, Gao Changshou, Fleming Ryan, Woods Robert M, Yao Xiao-Tao, Shirinian Lena, Kiener Peter A, Wu Herren
Department of Antibody Discovery and Protein Engineering, MedImmune, One MedImmune Way, Gaithersburg, MD 20878, USA.
J Mol Biol. 2009 Oct 30;393(3):672-92. doi: 10.1016/j.jmb.2009.08.032. Epub 2009 Aug 20.
Monoclonal antibodies are traditionally used to block the function of a specific target in a given disease. However, some diseases are the consequence of multiple components or pathways and not the result of a single mediator; thus, blocking at a single point may not optimally control disease. Antibodies that simultaneously block the functions of two or more disease-associated targets are now being developed. Herein, we describe the design, expression, and characterization of several oligospecific antibody formats that are capable of binding simultaneously to two or three different antigens. These constructs were generated by genetically linking single-chain Fv fragments to the N-terminus of the antibody heavy and light chains and to the C-terminus of the antibody C(H)3 domain. The oligospecific antibodies were expressed in mammalian cells, purified to homogeneity, and characterized for binding to antigens, Fcgamma receptors, FcRn, and C1q. In addition, the oligospecific antibodies were assayed for effector function, protease susceptibility, thermal stability, and size distribution. We demonstrate that these oligospecific antibody formats maintain high expression level, thermostability, and protease resistance. The in vivo half-life, antibody-dependent cellular cytotoxicity function, and binding ability to Fcgamma receptors and C1q of the test oligospecific antibodies remain similar to the corresponding properties of their parental IgG antibodies. The excellent expression, biophysical stability, and potential manufacturing feasibility of these multispecific antibody formats suggest that they will provide a scaffold template for the construction of similar molecules to target multiple antigens in complex diseases.
传统上,单克隆抗体用于阻断特定疾病中特定靶点的功能。然而,有些疾病是多种成分或途径导致的结果,而非单一介质所致;因此,单点阻断可能无法最佳地控制疾病。目前正在研发能够同时阻断两个或更多与疾病相关靶点功能的抗体。在此,我们描述了几种能够同时结合两种或三种不同抗原的多特异性抗体形式的设计、表达及特性。这些构建体是通过将单链Fv片段基因连接到抗体重链和轻链的N端以及抗体C(H)3结构域的C端而产生的。多特异性抗体在哺乳动物细胞中表达,纯化至均一,并对其与抗原、Fcγ受体、FcRn和C1q的结合进行特性分析。此外,还对多特异性抗体的效应功能、蛋白酶敏感性、热稳定性和大小分布进行了检测。我们证明这些多特异性抗体形式保持了高表达水平、热稳定性和蛋白酶抗性。测试的多特异性抗体的体内半衰期、抗体依赖性细胞毒性功能以及与Fcγ受体和C1q的结合能力与其亲本IgG抗体的相应特性相似。这些多特异性抗体形式出色的表达、生物物理稳定性和潜在的生产可行性表明,它们将为构建类似分子以靶向复杂疾病中的多种抗原提供一个支架模板。